I am following the results of this survey closely and will provide updates. Here, I focus on this question:
What challenges are presented in handling adverse event information from these sources?The survey asks respondents to choose one or more of the following responses (and/or add additional comments):
- The amount of information from these sources is potentially too vast to be processed economically (lack of resources)
- Finding adverse event information from these sources is like finding a needle in a haystack (too daunting)
- The information is usually incomplete and does not meet the requirements for submitting a meaningful AER (not actionable)
- There are many potential issues that won't fully be known until the practice of monitoring social media for AEs is more prevalent (unknown issues).
- None of the above
SPECIAL REPORT: FDA Regulation of Social Media
Find links to more results here.
In my opinion, it doesn't make much sense to put responsability of reporting on the manufacturers. I think adverse events should be evaluated and reported by the physicians who prescribe and/or follow up patients treatments and they should report by filling up an online application connected to an FDA database to which pharmaceutical companies should have access for further analysis and evaluation.
ReplyDeleteReports should include all the relevant information as a description of symptom/s experimented by patient and/or detected by physcian, drugs being taken by patient, dosage, etc.
Regards,
Miguel